Robert Mittendorff, Md, Mba

Nuvig Therapeutics is advancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following inflammation, and improve the treatment options for patients. Nuvig is building a pipeline of novel immune therapeutics for chronic inflammatory and autoimmune diseases.

Chronic inflammatory diseases are the most significant cause of death in the world, and those who live with them have a reduced quality of life. Many immunology-focused medications give patients a temporary fix to a longer-term problem—addressing symptom control rather than the root cause of disease. Evommune is different. We strive to develop accessible innovations that are meant to address symptoms as well as help avoid disease progression and medical complications in the future.

Volastra Therapeutics is a New York-based drug discovery and therapeutics company pioneering novel approaches to treating cancer by exploiting chromosomal instability (CIN), cancer’s most targetable vulnerability. Founded by Lewis Cantley, Ph.D., Olivier Elemento, Ph.D., and Samuel Bakhoum, M.D., Ph.D., Volastra is advancing a novel synthetic lethal and immune activating pipeline. Leading its portfolio, Volastra has two KIF18A inhibitors in Phase 1 clinical trials for cancers with high levels of chromosomal instability.

Nalu Medical, Inc. is a privately held commercial medical device company based in Carlsbad, California. The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The system is highly capable and easily upgradeable, providing a menu of therapy options.

Healthcare needs good data. At PicnicHealth, we are building deep real-world datasets fueling cutting edge research while giving patients control of their own medical record data. These complete, clinically-rich datasets produce unique insights - across dozens of diseases - to ultimately get the right treatments into patients’ hands faster. We do this by working directly with patients and leveraging state of the art machine learning and human curation to transform messy medical records into structured, research-ready datasets. To date, we’ve helped tens of thousands of patients securely access their records and proactively contribute to advancing research in diseases that impacts their lives. We partner with some of the largest life sciences companies (including 10 of the Top 30) and have raised more than $100M including a recently closed $60M Series C led by B Capital Group, with continued investments from Felicis Ventures and Amplify Partners, who also participated in the Series B.

At Triumvira Immunologics, Inc., our team is dedicated to a vision of finding a cure and providing new hope for patients with life-threatening disease. Co-founded in 2015 by licensing technology out of McMaster University and Bloom Burton & Co., Triumvira is working to achieve this vision by developing a proprietary T cell Antigen Coupler (TAC) technology, thought to be safer and more efficacious than current cancer treatments including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. We are an emergent US company with operations in the United States and Canada. We bring together talent from a wide range of disciplines including immunobiology, drug development, fundraising, commercialization and finance, with decades of experience across big pharma and small biotech, multiple industries and academia. We are passionate about science that pushes the limits, the patients that drive the heart of our work, and the wellness of our employees. We embrace flexibility. If you are looking for a career where you are encouraged to be innovative, challenge the status quo, and have some fun while doing it, Triumvira is the place for you. For more information about Triumvira career opportunities, please see our Careers web page at: https://triumvira.com/contact-us/careers/

Aetion is a health care analytics company that delivers real-world evidence for the manufacturers, purchasers, and regulators of medical treatments and technologies. The Aetion Evidence Platform® analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on safety, effectiveness, and value. Founded by Harvard Medical School faculty members with decades of experience in epidemiology and health outcomes research, Aetion informs health care’s most critical decisions — what works best, for whom, and when — to guide product development, commercialization, and payment innovation. Aetion is based in New York City and backed by investors including New Enterprise Associates (NEA), Warburg Pincus, Flare Capital Partners, Greenspring Associates, Lakestar, B Capital, Foresite Capital, Town Hall Ventures, McKesson Ventures, Sanofi Ventures, EDBI, Johnson & Johnson Innovation—JJDC, Inc., UCB, Amgen Ventures, and Horizon Health Services, Inc. Learn more at aetion.com and follow us at @aetioninc.

About Route 92 Medical, Inc. Route 92 Medical is on a mission to improve outcomes for patients undergoing minimally invasive brain procedures. At the core is a reconsidered procedural approach, cutting-edge engineering, and innovative product design. Our portfolio takes aim at the biggest challenges in neurointervention to deliver meaningful solutions to treat challenging diseases such as stroke. Founded by physicians, the company is focused upon developing thoughtful next generation products in collaboration with the world’s leading clinicians with the goal of improving procedural and patient outcomes. The Monopoint operating platform received U.S. FDA 510(k) clearance in 2020. The company is currently enrolling the SUMMIT MAX randomized controlled trial under an FDA-approved Investigational Device Exemption.

A leading provider of virtual mental health care, Talkspace provides convenient access to high-quality, evidence-based therapy, psychiatry, and self-guided support. The Talkspace network of 5,000+ licensed clinicians includes therapists and psychiatric providers with specialized knowledge of more than 150 conditions and treatment approaches. Founded in 2012, Talkspace pioneered message-based therapy, fulfilling an unmet desire of many people to text with a therapist, any time, from anywhere. We have grown into a single destination for comprehensive mental health care, including specialized therapy for individuals, couples, and teens, psychiatry and medication management, and self-guided tools and resources. All care is delivered through our fully-encrypted web and mobile platform that meets HIPAA, federal, and state regulatory requirements. More than 130 million people have access to Talkspace through their health plans for the cost of a copay or free through their employer, college or university, school district, or government agency. Making high-quality mental health support available to all is the Talkspace mission, and we’re just getting started.

For 15 years, Omada Health has been in the corner of millions of Americans managing chronic conditions. We help our members between doctor visits, providing virtual care that adapts to real life. We partner with employers, health plans, pharmacy benefit managers, and government agencies to support their populations across common chronic conditions — from prediabetes, diabetes, and hypertension to muscle and joint pain— all through the convenience of an app. Our programs also adapt to provide specialized care for GLP-1 journeys. At Omada, care isn’t built for perfection. It’s built for real people. Our clinically-validated programs combine human connection with modern technology, pairing members with real coaches and care teams. Omada’s impact is proven: our outcomes are published in 30 peer-reviewed studies, showing lasting behavior change, reduced healthcare costs, and ROI for our partners. Our success starts with our people. Omada’s strong, inclusive culture has earned us the Great Place to Work certification, and in 2025 we became a Nasdaq-listed company — a milestone on our mission to bend the curve of chronic disease.

Philips provides a comprehensive portfolio of flexible virtual care management solutions to motivate and connect with patients and members virtually anywhere. Our clinical protocols combined with smart devices, highly personalized engagement tools, plus our optional professional monitoring and personalized health coaching foster strong engagement and empower healthier behaviors. With Philips, you can unlock the power of human-centered care, improving patient and member health, virtually, every step of the way.

Philips provides a comprehensive portfolio of flexible virtual care management solutions to motivate and connect with patients and members virtually anywhere. Our clinical protocols combined with smart devices, highly personalized engagement tools, plus our optional professional monitoring and personalized health coaching foster strong engagement and empower healthier behaviors. With Philips, you can unlock the power of human-centered care, improving patient and member health, virtually, every step of the way.

We’re designing a better way to deliver and pay for health while engaging and guiding a community of members to live their best health. As a national, team-based medical group with a focus on wellbeing and prevention that extends beyond traditional sick care, we deliver Primary Health. An entirely new model of health, Primary Health is driven by an interdisciplinary team that builds relationships with members to proactively move them towards their best health using measurement-based care. Join our movement as we create the future of health as it should be.

We’re designing a better way to deliver and pay for health while engaging and guiding a community of members to live their best health. As a national, team-based medical group with a focus on wellbeing and prevention that extends beyond traditional sick care, we deliver Primary Health. An entirely new model of health, Primary Health is driven by an interdisciplinary team that builds relationships with members to proactively move them towards their best health using measurement-based care. Join our movement as we create the future of health as it should be.

iRhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine- learning capabilities. Our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ECG, monitoring for patients at risk for arrhythmias. We have created a unique platform, ZIO by iRhythm, which we believe allows physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies, avoiding multiple indeterminate tests, allowing for appropriate medical intervention and potentially avoiding more serious downstream medical events, including stroke.

Nuvig Therapeutics is advancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following inflammation, and improve the treatment options for patients. Nuvig is building a pipeline of novel immune therapeutics for chronic inflammatory and autoimmune diseases.

Chronic inflammatory diseases are the most significant cause of death in the world, and those who live with them have a reduced quality of life. Many immunology-focused medications give patients a temporary fix to a longer-term problem—addressing symptom control rather than the root cause of disease. Evommune is different. We strive to develop accessible innovations that are meant to address symptoms as well as help avoid disease progression and medical complications in the future.

Volastra Therapeutics is a New York-based drug discovery and therapeutics company pioneering novel approaches to treating cancer by exploiting chromosomal instability (CIN), cancer’s most targetable vulnerability. Founded by Lewis Cantley, Ph.D., Olivier Elemento, Ph.D., and Samuel Bakhoum, M.D., Ph.D., Volastra is advancing a novel synthetic lethal and immune activating pipeline. Leading its portfolio, Volastra has two KIF18A inhibitors in Phase 1 clinical trials for cancers with high levels of chromosomal instability.

Nalu Medical, Inc. is a privately held commercial medical device company based in Carlsbad, California. The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The system is highly capable and easily upgradeable, providing a menu of therapy options.